M&A Deal Summary

Cubist Pharmaceuticals Acquires Optimer Pharmaceuticals

On October 24, 2013, Cubist Pharmaceuticals acquired life science company Optimer Pharmaceuticals for 801M USD

Acquisition Highlights
  • This is Cubist Pharmaceuticals’ 5th transaction in the Life Science sector.
  • This is Cubist Pharmaceuticals’ largest (disclosed) transaction.
  • This is Cubist Pharmaceuticals’ 5th transaction in the United States.
  • This is Cubist Pharmaceuticals’ 1st transaction in New Jersey.

M&A Deal Summary
Date 2013-10-24
Target Optimer Pharmaceuticals
Sector Life Science
Buyer(s) Cubist Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 801M USD
Advisor(s) J.P. Morgan Securities
Centerview Partners (Financial)
Sullivan & Cromwell (Legal)

Target

Optimer Pharmaceuticals

Jersey City, New Jersey, United States
website
Optimer Pharmaceuticals, Inc., a biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and Canada, and developing other fidaxomicin products in the United States and worldwide, both independently and in our conjunction with partners and licensees.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cubist Pharmaceuticals

Lexington, Massachusetts, United States

website

Category Company
Founded 1992
Sector Life Science
Employees900
Revenue 1.1B USD (2013)
DESCRIPTION

Cubist Pharmaceuticals, Inc. is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

DEAL STATS #
Overall 5 of 5
Sector (Life Science) 5 of 5
Type (Add-on Acquisition) 5 of 5
State (New Jersey) 1 of 1
Country (United States) 5 of 5
Year (2013) 2 of 2
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-30 Trius Therapeutics

San Diego, California, United States

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Buy $707M
Mergr

Product

Company

Legal